FDA approves new drug for Alzheimer's disease: ‘Meaningful results' [FOX News]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: FOX News
The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer's disease Eli Lilly's Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease, according to a press release from the company. Eligible patients include those with mild cognitive impairment (MCI) and those who have mild dementia with confirmed amyloid pathology. This is the first medication to target amyloid plaques — the proteins that build up in the brains of Alzheimer's patients, often impairing memory and cognitive function — with evidence to support stopping therapy when amyloid plaques are removed, the release stated. "Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease, who urgently need effective treatment options," said Anne White, executive vice president and president of Lilly Neuroscience, Eli Lilly and Company , in the release. "We know these medicines have the gr
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $1,023.00 price target on the stock.MarketBeat
- Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio [Yahoo! Finance]Yahoo! Finance
- Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation [Yahoo! Finance]Yahoo! Finance
- Forget Eli Lilly: 3 Biotech Stocks to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Ozempic linked to rare cases of vision loss in Harvard study [Fortune]Fortune
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 7/3/24 - Form 4
- 7/2/24 - Form 4
- 7/1/24 - Form 4
- LLY's page on the SEC website